Organizers: Sunkyu Kim, Novartis; Kenneth LaMontagne, Johnson & Johnson; Pannie Trifillis, PTC Therapeutics
Hypoxia plays a crucial role in normal and tumor physiology. Studying how normal and tumor cells can sense and respond differently to hypoxia will allow a better understanding of cancer as a disease, and will hopefully also provide novel therapeutic opportunities for treating this disease. Much progress has been made regarding the biology of hypoxia during the past decade. At the 2006 BPDG Hypoxia symposium, the leading experts in the field will present their latest findings and hypotheses as well as their efforts at targeting tumor hypoxia for cancer treatment. The symposium hopes to provide an open forum for further discussions on these subjects by underscoring the new insights and further stimulating ideas for future cancer therapy.
8:30 AM: Registration and Check-in
9:00 - 9:15: Welcome and Introduction
Part I - The Biology of Hypoxia
9:15 - 10:00:
Mircea Ivan, Tufts University School of Medicine, "Hypoxia Regulation of the MicroRNA-ome: A New Layer of a Complex Response."
10:00 - 10:45:
Paul Schumacker, University of Chicago, "Oxygen Sensing by Mitochondria: Role of Reactive Oxygen Molecules in Regulating HIF."
10:45 - 11:30:
M. Celeste Simon, Howard Hughes Medical Institute, "HIFs, Hypoxia and Tumor Progression."
11:30 AM - 1:00 PM: Lunch Break
1:00 - 1:45:
Randall Johnson, University of California, San Diego, "The Physiology of Tumor Vascularization and Endothelial Hypoxic Response."
Part II - Therapeutic Approaches Targeting Hypoxia
1:45 - 2:30:
Giovanni Melillo, National Cancer Institute at Frederick, "Targeting HIF-1 for Development of Novel Cancer Therapeutics."
2:30 - 3:00: Coffee Break
3:00 - 3:45:
Andrew Kung, Dana-Farber Cancer Institute, "Targeting Tumor Hypoxic Transcription."
3:45 - 4:30:
Martin Brown, Stanford University, "Targeting Tumor Hypoxia: A Rational Approach to Cancer Therapy."
4:30 - 5:00: Panel Discussion